Segment Information

9 Months Ended

Mar. 31, 2019

Note 13. Segment Information

The Company operates in one reportable segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy and radiosurgery for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics.

Disaggregation of Revenues

The Company disaggregates its revenues from contracts by geographic region, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Additionally, the Company typically recognizes revenue at a point in time for product revenue and recognizes revenue over time for service revenue.

The following tables present net revenue and long-lived asset information based on geographic region. Net revenue is based on the destination of the shipments and long-lived assets are based on the physical location of the assets (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
Net Revenue	2019		2018		2019		2018
Americas	$	31,616	$	41,767	$	92,559	$	115,544
Europe, India, Middle East, and Africa		32,943		28,635		110,919		95,789
Asia Pacific		17,070		14,731		47,922		39,399
Japan		21,592		14,699		49,968		40,379
Total	$	103,221	$	99,832	$	301,368	$	291,111

	March 31,		June 30,
Property and equipment, net	2019		2018
Americas	$	16,640	$	19,698
Europe, India, Middle East, and Africa		609		569
Asia Pacific		1,632		1,635
Japan		1,384		1,796
Total	$	20,265	$	23,698